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(57) ABSTRACT 
Activated C3 (C3a) and its receptor (C3aR) and activated C5 
(C5a) and its receptor (C5aR) have been shoWn to induce 
vascular endothelial groWth factor (V EGF) expression in 
vitro and in vivo. Compositions and methods for inhibiting 
C3a, C3aR, C5a and C5aR for the treatment and/or preven 
tion of neovascular disease are provided. Also provided are 
Novel therapeutic targets and diagnostic markers for choroi 
dal neovasculariZation. 
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COMPOSITIONS AND METHODS FOR 
INHIBITING DRUSEN COMPLEMENT 
COMPONENTS C3A AND C5A FOR THE 
TREATMENT OF AGE-RELATED MACULAR 
DEGENERATION 
This application is a continuation-in-part to US. patent 
application Ser. No. 10/685,705 ?led Oct. 16, 2003 now US. 
Pat. No. 7,595,430 Which claims priority to US. provisional 
application Ser. No. 60/422,096, ?led Oct. 30, 2002, each of 
Which are incorporated herein in their entirety. 
GOVERNMENT SUPPORT 
This invention Was made With government support under 
grant numbers: (1) NIH EY015422 aWarded by the National 
Eye Institute of the National Institutes of Health (N EI/N IH), 
(2) 5T32DC000065 (training grant) aWarded by the National 
Institute on Deafness and Other Communication Disorders of 
the National Institutes of Health (NIDCD/NIH), (3) NIH 
GM62134 aWarded by the NIH, and (4) NIH GM069736 
aWarded by the NIH. The government has certain rights in the 
invention. 
FIELD OF THE INVENTION 
This invention relates to compositions and methods for 
treating and/or preventing age-related macular degeneration 
(AMD). More particularly, the invention relates to the use of 
antagonists and antibodies to activated complement compo 
nent 3 (C3a) and/or its receptor (C3aR), and activated 
complement components 5 (C5a) and/or its receptor (C5aR) 
to reduce vascular endothelial groWth factor (VEGF) expres 
sion and inhibit choroidal neovasculariZation (CNV). This 
invention also relates to an assay for the detection of C3a, 
C3aR, C5a and/or C5aR as a predisposition for and/or early 
detection of AMD. 
BACKGROUND OF THE INVENTION 
Age-related macular degeneration (AMD) is the leading 
cause of permanent vision loss among the elderly in many 
industrialized countries. Smith, W., Assink, J., Klein, R., 
Mitchell, P., Klayer, C. C., Klein, B. E., Hofman, A., Jensen, 
S., Wang, J. J. & de Jong, P. T. (2001) Ophthalmology 108, 
697-704. The majority ofvision loss due to AMD is a result of 
pathologic neW blood vessels, termed CNV, invading the 
retina from the underlying choroid through fractures in Bruch 
membrane, the extracellular matrix betWeen the choroid and 
the retinal pigment epithelium (RPE). The earliest clinical 
hallmark of AMD is the appearance of drusen (Gass, J. D. 
(1972) TransAm Ophthalmol Soc 70, 409-36), localiZed lipo 
proteinaceous deposits betWeen the RPE and Bruch mem 
brane. Although their presence is an epidemiological risk 
factor for the development of CNV (Bressler, S. B., Maguire, 
M. G., Bressler, N. M. & Fine, S. L. (1990)Arch Ophthalmol 
108, 1442-7; and Macular Photocoagulation Study Group 
(1997) Arch Ophthalmol 115, 741-7), the mechanism ofhoW, 
or if, drusen provoke CNV remains unde?ned. Some inves 
ti gators have suggested that drusen are epiphenomena, While 
others have claimed that drusen constituents act as a focal 
stimulus for in?ammatory cells that secrete angiogenic mol 
ecules such as VEGF, and still others have suggested that 
drusen disturb RPE homeostasis by impairing transport 
across Bruch membrane. RevieWed in Ambati, J ., Ambati, B. 
K., Yoo, S. H., Ianchulev, S. & Adamis, A. P. (2003) Surv 
Ophthalmol 48, 257-293. 
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Recent Work has demonstrated that complement compo 
nents C3 and C5 are principal constituents of drusen in 
patients With AMD. Mullins, R. F., Russell, S. R., Anderson, 
D. H. & Hageman, G. S. (2000) FASEB J 14, 835-46; 
Johnson, L. V., OZaki, S., Staples, M. K., Erickson, P. A. & 
Anderson, D. H. (2000) Exp Eye Res 70, 441 -9; Anderson, D. 
H., Mullins, R. F., Hageman, G. S. & Johnson, L. V. (2002) 
Am J Ophthalmol 134, 411-31; and Leitner, W. P., Staples, M. 
K. & Anderson, D. H. (2001) Exp Eye Res 73, 887-96. Their 
presence as Well as that of the membrane-attack-complex 
(MAC) C5b-9 and other acute phase reactant proteins in RPE 
cells overlying drusen has fueled speculation that drusen bio 
genesis involves chronic in?ammatory processes that either 
can trigger complement activation and formation of MAC 
acting to lyse RPE cells or disturb physiological homeostasis 
in RPE cells. Johnson, L. V., et al. (2001) Exp Eye Res 73, 
887-96. 
Recently We described an animal model of AMD in aged 
Ccl2_/_ and Ccr2_/_ mice, Which develop many salient patho 
logical features seen in the human condition. Ambati, J ., 
Anand,A., FemandeZ, S., Sakurai, E., Lynn, B. C., KuZiel, W. 
A., Rollins, B. J. & Ambati, B. K. (2003) Nat Med 9, 1390 
1397. Interestingly, RPE and choroidal deposits of C3 and C5 
also are found in these mice at a young age. The inability of 
these mice, Which are impaired in induced macrophage traf 
?cking, to clear these complement deposits is thought to 
promote the later development of CNV via upregulation of 
RPE cell secretion of VEGF. Id. These ?ndings suggest a 
mechanistic link betWeen deposition of complement compo 
nents in drusen and the development of CNV. 
There is groWing evidence that complement components 
are more than mere mediators of innate immunity. To date, 
their in?uence on the molecular regulation of angiogenesis in 
vivo has not been addressed. Because drusen predispose to 
and predate CNV, We explored Whether C3a and C5a (the 
activated forms) play a role in CNV development by studying 
their impact on VEGF expression, and also in laser-induced 
CNV, an accelerated model of neovascular AMD that repro 
duces much of the pathology and immunophenotype of 
human CNV (RevieWed in Ambati, J ., et al. (2003) Surv 
Ophthalmol 48, 257-293), using mice de?cient in receptors 
for C3a or C5a. The effect of modulating C3a and C5a reveals 
novel therapeutic strategies to modulate angiogenesis in the 
setting of in?ammation and highlights the importance of 
developing the ability to assay expression of markers such as 
C3a and C5a to for diagnostics and to target therapeutics more 
speci?cally. 
SUMMARY OF THE INVENTION 
In one aspect of the invention there is provided composi 
tions for treating and/ or preventing AMD. In one embodiment 
there are ophthalmic compositions for treating and/or pre 
venting CNV comprising one or more of, an inactivating 
agent that binds selectively to C3a and/ or its receptor (C3aR), 
an inactivating agent to C5a and/or its receptor (C5aR), or a 
combination thereof. In a preferred embodiment the one or 
more inactivating agent is an antagonist to C3a, C3aR, C5a, 
C5aR, or a combination thereof. In another preferred embodi 
ment, the one or more inactivating agent is an antibody. In still 
another preferred embodiment, the compositions further 
comprise one or more pharmaceutical agent operatively 
attached to the inactivating agent. In another aspect of the 
invention there is provided methods of using the composi 
tions described herein to inhibit VEGF expression; to inhibit 
CNV; to prevent and/ or treat AMD. 
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In another aspect of the invention there is provided meth 
ods for treating and/ or preventing AMD. In one embodiment 
there are methods for treating and/ or preventing CNV com 
prising administering to the eye of a subject a therapeutically 
effective amount of a composition comprising one or more of, 
an inactivating agent that binds selectively to C3a, C3aR, 
C5a, C5aR, or a combination thereof. In a preferred embodi 
ment the one or more inactivating agent is an antagonist to 
C3a, C3aR, C5a, C5aR or a combination thereof. In another 
preferred embodiment, the one or more inactivating agent is 
an antibody. Preferably, administration of such one or more 
antagonist or antibody to C3a, C3aR, C5a or C5aR reduces 
VEGF expression. In still another preferred method, the inac 
tivating agent is operatively attached to one or more pharma 
ceutical agent, having therapeutic or toxic effects. 
In another aspect of the invention there is provided meth 
ods, assays and kits for detecting the presence of C3a, C3aR, 
C5a and/or C5aR for diagnostic and treatment purposes. In a 
preferred embodiment, one or more of, an antibody to C3a, 
C3aR, C5a, C5aR, or a combination of both is introduced to 
the eye or to a sample from the eye of a patient and the 
presence of C3a, C3aR, C5a and/or C5aR is detected. Pref 
erably, antibody is labeled With a detectable label. Examples 
of such detectable labels include those that are, for example, 
radioactive, ?uorescent, chemiluminescent or absorbant 
based, or a combination of the foregoing. The presence of 
C3a, C3ar, C5a, C5aR or a combination thereof is detected by 
determining Whether an antibody binds selectively to a com 
ponent of the eye. Detection or increased level of C3a, C3aR, 
C5a and/or C5aR in comparison to levels of a sample from a 
normal subject is indicative of a predisposition for or neovas 
cular disease, like AMD. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 (A-B). C3a and C5a upregulate VEGF in vitro and 
in vivo. Human C3a (50 ng/ml) and C5a (50 ng/ml) upregu 
lated human RPE cell secretion of VEGF (A). Intravitreous 
injection of human C3a or C5a increase VEGF levels in the 
RPE/choroid (solid lines) but not in the neurosensory retina 
(dotted lines) in a dose-dependent fashion 4 hours after inj ec 
tion (B). *P<0.05 compared to PBS (A) and to 0 ng (B). 
FIG. 2 (A-G). Laser injury induces C3 and C5 deposition. 
Western blotting shoWs increasing levels of C3 and C5 in the 
RPE/choroid of Wild-type mice Within 6 hours of injury and is 
sustained for at least 24 hours (A). C5 (B,C,D) and C3 (E,F,G) 
are deposited (red) in the RPE cell layer and on the apical 
surface of RPE cells in the area of injury (B,E) and next to the 
area of injury (C,F) 12 hours after injury, but not in uninjured 
areas (D,G). ArroWs shoW RPE cell nuclei. Ch:choroid, 
PRrphotoreceptor nuclei, Scl:sclera. Scale bar 20 um. 
FIG. 3 (A-B). Laser-induced VEGF induction is dimin 
ished in C3aR_/_ and C5aR_/_ mice. VEGF levels in the 
RPE/choroid, Which peak 3 day after laser injury (A) are 
signi?cantly reduced in both knockout strains (B). *P<0.05 
compared to level before injury (A) and to Wild-type (Wt) 
mice (B). 
FIG. 4 (A-D). Leukocyte recruitment to the choroid is 
diminished in C3aR_/_ and C5aR_/_ mice. Neutrophil in?l 
tration (normalized to peak), Which peaks 1 day after laser 
injury (A) is signi?cantly reduced in both knockout strains 
(B). Macrophage in?ltration (normalized to peak), Which 
peaks 3 days after laser injury (C) is signi?cantly reduced in 
both knockout strains (D). *P<0.05 compared to number of 
cells before injury (A,C) and to Wild-type (Wt) mice (B,D). 
FIG. 5 (A-D). CNV is reduced in knockout mice. Stacked 
confocal images (1 pm sections) of FITC-isolectin B4 labeled 
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tissue Within laser scars in Wild-type (A), C3aR_/_ (B) and 
C5aR_/_ (C) mice demonstrate more than 40% reduction in 
CNV volume (D). *P<0.05 compared to Wild-type (Wt) mice. 
Scale bar 100 um. 
FIG. 6 (A-B). (A) CNV is reduced in Wild-type mice 
treated With C3aRA or C5aRA compared With control pep 
tide, only if inj ected immediately after laser injury. (B) CNV 
is reduced in Wild-type mice treated With neutralizing anti 
C3a or anti-C5a antibodies compared With isotype control 
antibodies, only if injected immediately after laser injury. 
DETAILED DESCRIPTION OF THE INVENTION 
All publications, patents and patent applications cited 
herein, Whether supra or infra, are hereby incorporated by 
reference in their entirety. 
As used herein, the term “antagonist” means any molecule 
that binds to certain proteins (e.g., receptors, enzymes) at a 
speci?c (active) site on that protein, Which binding sup 
presses, inhibits, impedes or neutralizes the activity (func 
tion) or effect of the protein. 
As used herein, the terms “bind”, “binding” or “bound” 
mean any interaction, Whether via direct or indirect means, 
Whichbinds, combines, couples, links, or unites molecules by 
means of reactive groups, either in the molecules per se or in 
a chemical added for that purpose, as in the affects of, for 
example, a speci?ed protein, receptor or protein/receptor sub 
unit, antibody-antigen interaction, covalent binding, and any 
non-covalent binding including disul?de bonds, Vander 
Waals, electrostatic force, and hydrostatic force. 
As used herein, the term “binds selectively to” means that 
the inactivating agent, including antagonists, antibodies, 
compounds, compositions, formulation, nucleic acids, etc., 
binds to one or more of C3a, C3aR, C5a, or C5aR. 
As used herein, the term “detectable label(s)” are com 
pounds or elements that can be detected due to their speci?c 
functional properties, or chemical characteristics, the use of 
Which alloWs the component to Which they are operatively 
attached to be detected, and further quanti?ed if desired. 
As used herein, the term “diagnostically effective” means 
that the amount of detectably labeled compound, such as 
monoclonal antibody or other compound, is administered in 
suf?cient quantity to enable detection of C3a, C3aR, C5a 
and/or C5aR for Which the antibodies or compounds are 
speci?c. 
As used herein, the term “expression” means the detectable 
effect of a gene, like a nucleic acid sequence encoding VEGF. 
The term “express” means to manifest the detectable effect of 
a gene. A gene may be expressed inside a cell, on the surface 
of a cell or be secreted by the cell. 
As used herein, the term “inactivate” refers to the act of 
inhibiting, preventing, suppressing or neutralizing C3a, 
C3aR, C5a and/or C5aR function to induce VEGF expres 
sion. 
As used herein the term “inactivating agent” encompasses 
a group of functionally or structurally related proteins or 
small molecules, compounds or antibodies that modulate, 
bind to, and/ or inactivate C3a, C3aR, C5a and/or C5a, and/ or 
prevent C3a, C3aR, C5a and/or C5aR from inducing VEGF 
expression. Preferably, toxic side-effects are minimized. By 
“inactivating” it is meant that the agent may functionally 
inhibit, prevent, neutralize or suppress, C3a, C3aR, C5a and/ 
or C5aR activity (function) that leads to VEGF expression. 
As used herein, the term “introducing” means any means of 
delivery or administration, Whether in vivo or in vitro, includ 
ing simple contact. 
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As used herein, the term “neovascular disease” refers to 
age-related macular degeneration (AMD), including Wet 
AMD (classic, occult, subfoveal, extrafoveal, juxtafoveal) 
and dry AMD, cancer, choroidal neovasculariZation, corneal 
neovasculariZation, cystoid macular edema, diabetic retin 
opathy, diabetic macular edema (DME), in?ammatory or 
mechanical macular degeneration, iris neovasculariZation, 
myopic macular degeneration, macular degeneration due to 
histoplasmosis or angioid streaks or inherited retinal or cho 
roidal dystrophies/degenerations, proliferative diabetic retin 
opathy, psoriasis, retinal neovasculariZation, vitreal neovas 
culariZation, branch/central retinal vein occlusion, 
retinopathy of prematurity, rheumatoid arthritis, uveitis, or 
infection. 
As used herein, the term “neovasculariZation” means pro 
liferation of blood vessels in tissue not normally containing 
them, or proliferation of blood vessels of a different kind than 
usual in tissue. Non-limiting examples of ocular neovascu 
lariZation include neovasculariZation of the choroid (includ 
ing, classic, occult, Type 1, and Type 2 choroidal), cornea, 
iris, retina, retinal pigmented epithelium (RPE), and/ or vitre 
ous. Ocular neovasculariZation is also associated With eye 
neovascular disease such as, for example, AMD, choroidal 
neovasculariZation, cystoid macular edema, DME, diabetic 
retinopathy, in?ammatory diabetic retinopathy, retinopathy 
of prematurity, and traumatic eye injury. 
As used herein, the term “operatively attached” means 
association With, or attachment, conjugation, linking, orbind 
ing (direct or indirect by use of another molecule, linker, etc.) 
of one molecule, including compounds, labels and ligands, 
amino acid sequence, or nucleic acid sequence, to another 
molecule in such a Way as to alloW each of the molecules to 
function in their intended manners. 
As used herein, the term “patient” includes members of the 
animal kingdom including but not limited to human beings. 
The inventor has discovered that signi?cant quantities of 
complement components C3 and C5 are present Within the 
RPE/choroid soon after laser injury, and that laser-induced 
CNV is signi?cantly reduced in C3aR_/_ and C5aR_/_ mice 
via concerted suppression of leukocyte recruitment and 
VEGF expression. The inventor has also demonstrated that 
C3a and C5a upregulate RPE/choroid production of VEGF in 
the uninjured eye in a dose-dependent manner, consistent 
With their ability to upregulate RPE cell secretion of VEGF in 
vitro, and that VEGF upregulation induced by laser injury is 
abrogated in C3aR_/_ and C5aR_/_ mice. 
In disease states such as AMD Where the integrity of the 
RPE cell monolayer is compromised in some but not all 
regions, RPE cells Would be expected to exist both con?uent 
(quiescent) and subcon?uent (proliferating) conditions. In 
both conditions the inventor discovered that C3a and C5a 
induced VEGF in RPE cells. Both C3a and C5a upregulated 
the secretion of VEGF by human RPE cells, both in con?uent 
and subcon?uent conditions (FIG. 1A), but not in human 
choroidal endothelial cells (CEC; data not shoWn) in vitro, 
con?rming a previous observation about the effect of C5a. 
Ambati, 1., Anand,A., Fernandez, S., Sakurai, E., Lynn, B. C., 
KuZiel, W. A., Rollins, B. 1., Ambati, B. K. (2003) NatMed 9, 
1390-1397. This response Was preserved in vivo as intravit 
reous injection of C3a or C5a in Wild-type mice upregulated 
VEGF expression in the RPE/choroid in a dose-dependent 
fashion Within 4 hours of administration (FIG. 1B). The 
absence of a similar effect in the neurosensory retina demon 
strated that VEGF upregulation Was not a non-speci?c 
response to intraocular injection. 
In the laser injury model, the initial rise in VEGF levels 
occurred prior to the in?ltration of leukocytes (Sakurai, E., 
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Anand, A., Ambati, B. K., van Rooijen, N. & Ambati, 1. 
(2003) Invest Ophthalmol V1.3‘ Sci 44, 3578-85), suggesting 
that resident cells such as CBC and RPE cells are responsible. 
There Was no increase in the number of macrophages or 
neutrophils in the choroid 4 hours after intravitreous injection 
of C3a or C5a, indicating that the increase in VEGF expres 
sion Was due to resident cells (data not shoWn). C3 and C5 
expression Was detected by Western blotting in the RPE/ 
choroid Within 6 hours of injury, Which persisted for at least 
24 hours (FIG. 2A). Immunostaining revealed signi?cant 
amounts of C3 and C5 deposition in and near RPE cells in the 
area of injury (FIGS. 2B,E). RPE cells adjacent to the site of 
injury also stained for C3 and C5, While uninjured areas 
exhibited minimal if any staining for these complement com 
ponents (FIGS. 2C,D,F,G). The absence of an effect of C3a or 
C5a on CBC in vitro corresponded With the negligible stain 
ing of C3 or C5 in the choroid folloWing laser injury. The peak 
of the VEGF response 3 days after injury parallels the in?l 
tration of macrophages and can be blunted by macrophage 
depletion, suggesting that it is these recruited cells that are 
responsible for the second surge in VEGF. 
The inventor has found that there is no signi?cant increase 
in VEGF levels at any time point in C3aR_/_ and C5aR_/_ 
mice folloWing injury. VEGF levels in the RPE/choroid one 
day after injury Were signi?cantly reduced in C3aR_/_ 
(48.6%:7.5%; P:0.06) and C5aR_/_ mice (55.4%:3.1%; 
P:0.04) compared to Wild-type mice. The lack of an initial 
rise in VEGF immediately after injury in these animals is 
attributed to the disruption of C3a and C5a induced VEGF. 
Reduced VEGF levels persisted even 3 days after injury 
(FIG. 3A), the time point of the peak of the VEGF response 
(Sakurai, E., Anand, A., Ambati, B. K., van Rooijen, N. & 
Ambati, 1. (2003) Invest Ophthalmol 171s Sci 44, 3578-85), in 
C3aR'/' (60.9%:4.9%; P:0.01) and C5aR'/' mice 
(62.5%:3.1%; P:0.004) compared to Wild-type mice (FIG. 
3B). The peaks of VEGF in C3aR_/_ and C5aR_/_ mice fol 
loWing laser injury Were not elevated above pre-injury levels 
in Wild-type mice (P:0.99). The missing secondary surge in 
VEGF in C3aR_/_ and C5aR_/_ mice might be due both to the 
interference With complement component receptor mediated 
signaling and also the reduction in leukocyte recruitment. 
Leukocyte recruitment, Which plays a pivotal role in laser 
induced CNV (Sakurai, E., Taguchi, H., Anand, A., Ambati, 
B. K., Gragoudas, E. S., Miller, 1. W.,Adamis,A. P. &Ambati, 
1. (2003) Invest Ophthalmol 171s Sci 44, 2743-9; and Sakurai, 
E., Anand, A., Ambati, B. K., van Rooijen, N. & Ambati, 1. 
(2003) Invest Ophthalmol 171s Sci 44, 3578-85), Was also 
markedly reduced in C3aR_/_ and C5aR_/_ mice folloWing 
injury. The peak of neutrophil in?ltration into the choroid, 
Which occurred 1 day after injury (FIG. 4A), Was reduced in 
C3aR'/' (57.8%:9.0%; P:0.05) and C5aR'/' mice 
(66.6%:1.7%; P:0.02) compared to Wild-type mice (FIG. 
4B). The peak of macrophage in?ltration into the choroid, 
Which occurred 3 days after injury (FIG. 4C), Was reduced in 
C3aR'/' (49.1%:4.6%; P:0.04) and C5aR'/' mice (42.1%+ 
2.1%; P:0.05) compared to Wild-type mice (FIG. 4D). This 
may be due to direct interception of the chemotactic function 
of C3aR and C5aR on leukocytes or reduction in VEGF, 
Which itself is a chemoattractant. Barleon, B., SoZZani, S., 
Zhou, D., Weich, H. A., Mantovani, A. & Mar'me, D. (1996) 
Blood 87, 3336-43; and Clauss, M., Weich, H., Breier, G., 
Knies, U., Rockl, W., Waltenberger, 1. & Risau, W. (1996) J 
Biol Chem 271, 17629-34. It also may result from indirect 
reduction of chemokines such as Ccl-2 and Cxcl-2, Which the 
inventor and others have shoWn can be induced by comple 
ment components. Ambati, 1., Anand, A., FemandeZ, S., 
Sakurai, E., Lynn, B. C., KuZiel, W. A., Rollins, B. 1. & 
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Ambati, B. K. (2003) Nat Med 9, 1390-1397; Fukuoka, Y., 
Strainic, M. & Medof, M. E. (2003) Clin Exp Immunol 131, 
248-53; CZermak, B. J., Sarma, V., Bless, N. M., Schmal, H., 
Friedl, H. P. &Ward, PA. (1999) Jlmmunol 162, 2321-5; and 
Laudes, I. J., Chu, J. C., Huber-Lang, M., Guo, R. F., Riede 
mann, N. C., Sarma, J. V., Mahdi, E, Murphy, H. S., Speyer, 
C., Lu, K. T., Lambris, J. D., Zetoune, F. S. & Ward, P. A. 
(2002) Jlmmunol 169, 5962-70. 
While RPE cells constitutively produce both Ccl-2 (Elner, 
V. M., Bumstine, M.A., Strieter, R. M., Kunkel, S. L. & Elner, 
S. G. (1 997) Exp EyeRes 65, 781-9; and Holtkamp, G. M., De 
Vos, A. F., Peek, R. & Kijlsta, A. (1999) Clin Exp Immunol 
118, 35-40) andVEGF (Adamis, A. P., Shima, D. T.,Yeo, K. 
T., Yeo, T. K., BroWn, L. F., Berse, B., D’Amore, P. A. & 
Folkman, J. (1993) Biochem Biophys Res Commun 193, 631 
8), the stimuli inducing their overexpression in human CNV 
(Grossniklaus, H. E., Ling, J. X., Wallace, T. M., Dithmar, S., 
LaWson, D. H., Cohen, C., Elner, V. M., Elner, S. G. & 
Stemberg, P., Jr. (2002) Mol [6s 8, 119-26; Frank, R. N., 
Amin, R. H., Eliott, D., Puklin, J. E. &Abrams, G. W. (1996) 
Am J Ophthalmol 122, 393-403; and Lopez, P. F., Sippy, B. 
D., Lambert, H. M., Thach, A. B. & Hinton, D. R. (1996) 
Invest Ophthalmol J/Is Sci 37, 855-68) are unknown. The 
demonstration that C3a and C5a can trigger Ccl-2 and VEGF 
production make them attractive candidates as markers and 
modulators of CNV given their presence in drusen deposits in 
patients WithAMD and in a mouse model of AMD, as Well as 
folloWing laser injury, particularly because they can be 
locally synthesiZed in the RPE. Mullins, R. F., et al. (2000) 
FASEB J 14, 835-46; and Johnson, L. V., et al. (2000) Exp Eye 
Res 70, 441-9. 
By intercepting speci?c receptor-mediated pathways, the 
inventor has identi?ed a novel mechanistic association 
betWeen the complement and cytokine netWorks in promot 
ing laser-induced CNV. These ?ndings introduce the C3a and 
C5a complement factors as modulators of angiogenesis in the 
eye. These ?ndings also translate into functional inhibition. 
The volume of laser-induced CNV Was signi?cantly 
reduced in C3aR_/_ (41.5%:5.2%; n:13; P<0.001) and 
C5aR_/_ mice (40.8%:4.3%; n:14; P<0.001) compared to 
Wild-type mice (n:17) (FIG. 5). To complement the genetic 
ablation studies, the inventor tested neutraliZing antibodies 
against C3a or C5a and peptide antagonists of their receptors 
in Wild-type mice. CNV Was signi?cantly reduced by treat 
ment With both peptide antagonists and both neutraliZing 
antibodies, compared to control peptide or antibodies, if these 
blockers Were injected immediately after laser injury but not 
if they Were injected 3 days later (FIG. 6). These data indicate 
that the bulk of the pro-angiogenic effects of C3a and C5a in 
this model can be attributed to the very early release and 
deposition of these activated complement components. Sup 
pression of CNV in C3aR_/_ and C5aR_/_ mice, and in Wild 
type mice treated With antagonists of the activated comple 
ment components or their receptors also may be due to 
doWnregulation of leukocyte-endothelial adhesion mol 
ecules, Which can be promoted by C3a and C5a (Albrecht, E. 
A., Chinnaiyan, A. M., Varambally, S., Kumar-Sinha, C., 
Barrette, T. R., Sarma, J. V. & Ward, P. A. (2004) Am J Pathol 
164, 849-859; Ross, G. D., Cain, J. A. & Lachmann, P. J. 
(1985) J Immunol 134, 3307-15; and Lo, S., Detmers, P., 
Levin, S. & Wright, S. (1989) J Exp. Med. 169, 1779-1793) 
and are critical for CNV formation. Sakurai, E., et al., (2003) 
Invest Ophthalmol VJS Sci 44, 2743-9. 
Compositions of the Invention 
In one aspect of the invention there is provided composi 
tions comprising C3a, C3aR, C5a, and/or C5aR inactivating 
agents for treating and/or preventing AMD. In a preferred 
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embodiment there is ophthalmic compositions to treat and/ or 
prevent choroidal neovasculariZation by reducing VEGF. The 
compositions comprise one or more of, an inactivating agent 
that binds selectively to C3a, C3aR, C5a, C5aR, or a combi 
nation thereof. 
The inactivating agent may be an antagonist, antibody, 
anti-sense oligonucleotide, aptamer, miRNA, riboZyme, 
siRNA, or small molecule. In a preferred embodiment of this 
aspect of this invention, the inactivating agent is an antagonist 
to C3a, C3aR, C5a and/or C5aR. Non-limiting examples of an 
antagonist of the invention include the C3aR antagonist 
(C3aRA) N2-[(2,2-diphenylethoxy)acetyl]-1-arginine, the 
C3a and C3aR antagonists disclosed in US. Pat. Nos. 5,942, 
405 and 6,489,339, the C5aR antagonist (C5aRA) AcF-[OP 
dChaWR], and the C5aR antagonists disclosed in US. Pat. 
Nos. 6,916,830, 6,884,815, 6,858,637, 6,821,950, 6,777,422, 
6,723,743, 6,355,255, 6,270,775, 5,846,547, 5,837,499, 
5,807,824, 4,772,584, 4,692,511, or similar peptidases or a 
combination thereof. Methods to identify other antagonists 
are described in US. Pat. Nos. 5,861,272 and 5,614,370. 
Other antagonists to C3a, C3aR, C5a and/or C5a knoWn to the 
skilled artisan or hereafter discovered may be used. Candi 
date antagonists include pharmaceutical compounds, small 
molecules, peptides, nucleic acids, including oligonucle 
otides and polynucleotides in sense or antisense orientation 
and aptamers. 
In another preferred embodiment of this aspect of the 
invention, the inactivating agent is an antibody or functional 
antibody fragment (Fab) to C3a, C3aR, C5a and/or C5a. 
Preferably, the agent is an antagonist to C3a, C3aR, C5a 
and/or C5aR. It is also preferable that the agent is an antibody 
to C3a, C3aR, C5a and/or C5aR. Non-limiting examples of 
antibodies of the invention, include MAb anti-C3a from 
Quidel, San Diego, Calif. [catalog no. A203,]; anti-human 
C3aR antibodies hC3aRZ1 and hC3aRZ2, as described in 
Kacani, L. et al., J. Immunol. (2001) 166:3410-3415; mouse 
anti-human C5a antibodies from Hycult Biotechnology BV 
of the Netherlands [clones 557, 2942 and 2952]; anti-human 
C5a antibody from Tanox, Inc. [137-26], as described in 
Fung, M. et al. Clin Exp Immunol. (2003) August; 133(2): 
160-9; C5a antibodies disclosed in US. Pat. No. 5,480,974; 
anti-EXl human C5aR MAb S5/ 1, as described in Oppera 
mann, M., et al., J. Immunol. (1993) October 1; 151(7):3785 
94; and anti-C5aR MAb S5/1, as described in Kacani, L. et 
al., J. Immunol. (2001) 166:3410-3415. Anti-C3 and anti-C5 
antibodies may also function to inhibit C3a and/or C3aR or 
C5a and/or C5aR, respectively, such as, for example, goat 
polyclonal anti-human C5 antibody from Quidel, San Diego, 
Calif. [catalog no.A306].Ahybridoma that produces amono 
clonal anti-C3a, anti-C3aR, anti-C5a and/or anti-C5a anti 
body that binds to substantially the same epitope as any of the 
foregoing antibodies is another aspect of the invention. The 
antibodies may be polyclonal antibodies or monoclonal anti 
bodies. 
Polyclonal antibodies to C3a, C3aR, C5a and C5a can be 
produced by various procedures Well knoWn in the art. For 
example, puri?ed C3aR, preferably human C3aR, can be 
administered to various host animals including, but not lim 
ited to, rabbits, mice, rats, etc. to induce the production of sera 
containing polyclonal antibodies speci?c for the antigen. 
Various adjuvants may be used to increase the immunological 
response, depending on the host species, and include but are 
not limited to, Freund’s (complete and incomplete), mineral 
gels such as aluminum hydroxide, surface active substances 
such as lysolecithin, pluronic polyols, polyanions, peptides, 
oil emulsions, keyhole limpet hemocyanins, dinitrophenol, 
and potentially useful human adjuvants such as BCG (bacille 
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Calmette-Guerin) and corynebaclerium parvum. Such adju 
vants are also Well known in the art. 
The use of monoclonal antibodies (MAbs) or derivatives 
thereof to C3a, C3aR, C5a and/or C5aR is preferred. MAbs 
are recognized to have certain advantages, e. g., reproducibil 
ity and large-scale production, that makes them suitable for 
clinical treatment. The invention thus preferably provides 
monoclonal antibodies of the murine, human, monkey, rat, 
hamster, rabbit and even frog or chicken origin. Murine, 
human or humanized monoclonal antibodies Will generally 
be preferred. Preferably the anti-C3a antibody, anti-C3aR 
antibody, anti-C5a antibody, and anti-C5aR antibody are neu 
tralizing humanized rat or mouse lgG2a against human C3a, 
C3aR, C5a and C5a, respectively. 
Monoclonal antibodies to C3a, C3aR, C5a and C5aR can 
be prepared using a Wide variety of techniques knoWn in the 
art including the use of hybridoma, recombinant, and phage 
display technologies, or a combination thereof. For example, 
monoclonal antibodies can be produced using hybridoma 
techniques including those knoWn in the art and taught, for 
example, in HarloW et al., Antibodies: A Laboratory Manual, 
(Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Ham 
merling, et al., in: Monoclonal Antibodies and T-Cell Hybri 
domas 563-681 (Elsevier, N.Y., 1981). An exemplary anti 
body to C5a is described in US. Pat. No. 5,177,190. 
The ophthalmic compositions of this invention may further 
comprise one or more pharmaceutical agent operatively 
attached to the inactivating agent. In the context of the present 
invention the selected pharmaceutical agent is thus targeted to 
the RPE/choroid area of the eye by the inactivating agent, 
alloWing selective inhibition of C3a, C3aR, C5a and/ or C5aR 
activity and/ or treatment of an eye. The pharmaceutical agent 
may comprise therapeutic agents such as any compound, 
drug, molecule or protein having a desired therapeutic effect, 
including, for example, the breakdoWn or clearance of 
drusen, inhibition of CNV, inhibition of C3a, C3aR, C5a or 
C5aR activity and/or the inhibition of VEGF expression. 
Such other therapeutic agents may include anti-allergics, 
anti-angiogenics, anti-biotics, anti-cancer agents, anti-infec 
tives, anti-in?ammatory agents, dry eye solutions, steroids, 
and the like. This list is, of course, merely exemplary in that 
the technology for attaching pharmaceutical agents to antago 
nists for speci?c delivery to tissues is Well established. 
A toxin bound anti-C3a, anti-C3aR, anti-C5a, or anti 
C5aR antibody of the present invention comprises immuno 
toxins. The preparation of immunotoxins is, in general, Well 
knoWn in the art (see, e.g., US. Pat. No. 4,340,535, and EP 
4416), hoWever, certain advantages may be achieved through 
the application of certain preferred technology, both in the 
preparation of the immunotoxins and in their puri?cation for 
subsequent clinical administration. For example, While lgG 
based immunotoxins Will typically exhibit better binding 
capability and sloWer blood clearance than their Fab‘ coun 
terparts, Fab‘ fragment-based immunotoxins Will generally 
exhibit better tissue penetrating capability as compared to 
lgG based immunotoxins. 
Additionally, While numerous types of disul?de-bond con 
taining linkers are knoWn Which can successfully be 
employed to conjugate the toxin moiety With the antibody 
inactivating agent, certain linkers Will generally be preferred 
over other linkers, based on differing pharmacologic charac 
teristics and capabilities. For example, linkers that contain a 
disul?de bond that is sterically “hindered” are to be preferred, 
due to their greater stability in vivo, thus preventing release of 
the toxin moiety prior to binding at the site of action. 
Cross-linking reagents are used to form molecular bridges 
that tie together functional groups of tWo different proteins 
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(e.g., a toxin and an inactivating agent). To link tWo different 
proteins in a step-Wise manner, hetero bifunctional cross 
linkers can be used Which eliminate the unWanted homopoly 
mer formation. An exemplary hetero bifunctional cross 
linker contains tWo reactive groups: one reacting With 
primary amine group (e.g., N-hydroxy succinimide) and the 
other reacting With a thiol group (e.g., pyridyl disul?de, male 
imides, halogens, etc.). Through the primary amine reactive 
group, the cross-linker may react With the lysine residue(s) of 
one protein (e.g., the selected antibody or fragment) and 
through the thiol reactive group, the cross-linker, already tied 
up to the ?rst protein, reacts With the cysteine residue (free 
sulfhydryl group) of the other protein (e. g., dgA). 
The spacer arm betWeen these tWo reactive, groups of any 
cross-linkers may have various lengths and chemical compo 
sitions. A longer spacer arm alloWs a better ?exibility of the 
conjugate components While some particular components in 
the bridge (e. g., benzene group) may lend extra stability to the 
reactive group or an increased resistance of the chemical link 
to the action of various aspects (e.g., disul?de bond resistant 
to reducing agents). 
Non-limiting examples of toxic agents to bind to anti-C3a, 
anti-C3aR, anti-C5a, or anti-C5aR antibodies include any 
chemical agents having localized cytotoxic effects and radio 
isotopes. Exemplary radioisotopes that can be operatively 
attached to an inactivating agent include ot-emitters such as, 
for example, 21 lAstatine, 212Bismuth and 213 Bismuth, as Well 
as [3-emitters such as, for example, 131Iodine, 9OYttrium, 
177Lutetium, 15 3 Samarium and 109 Palladium. Particularly 
preferred radioisotopes are 211Astatine and 131Iodine. This 
list is, of course, merely exemplary in that the technology for 
attaching pharmaceutical agents to antibodies for speci?c 
delivery to tissues is Well established. 
The ophthalmic compositions of the present invention may 
still further comprise one or more anti-in?ammatory agent 
operatively attached to an inactivating agent. The ophthalmic 
compositions of the present invention may contain one or 
more inactivating agent that binds selectively to C3a, C3aR, 
C5a and/or C5aR With one or a combination of a steroid drug, 
such as triamcinolone, ?uocinolone, anacortave acetate, dex 
amethasone and combinations thereof; or a non-steroidal 
anti-in?ammatory drug, such as celecoxib, ?urbiprofen, and 
aspirin, for example. 
The ophthalmic compositions of this invention may still 
further comprise a pharmaceutically acceptable carrier. Such 
pharmaceutical carriers can be sterile liquids, such as Water 
and oils, including those of petroleum, animal, vegetable or 
synthetic origin, such as peanut oil, soybean oil, mineral oil, 
and the like. Saline solutions and aqueous dextrose, polyeth 
ylene glycol (PEG) and glycerol solutions can also be 
employed as liquid carriers, particularly for injectable solu 
tions. Suitable pharmaceutical excipients include starch, glu 
cose, lactose, sucrose, gelatin, malt, rice, sodium stearate, 
glycerol monostearate, glycerol, propylene, glycol, Water, 
and the like. The composition, if desired, can also contain 
minor amounts of Wetting or emulsifying agents, or pH buff 
ering agents. The C3a and C5a inactivating agents, and any 
combinations thereof or other active agents of the composi 
tion may be encased in polymers or ?brin glues to provide 
controlled release of the active agents. These compositions 
can take the form of solutions, suspensions, emulsion, tablets, 
pills, capsules, poWders, sustained-release formulations and 
the like. Examples of suitable pharmaceutical carriers are 
described in “Remington’s Pharmaceutical Sciences” by E. 
W. Martin. Such compositions Will contain a therapeutically 
effective amount of one or more of the inactivating agent, 
preferably in puri?ed form, together With a suitable amount of 
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carrier so as to provide the form for proper administration to 
the patient. The formulation should suit the mode of admin 
istration. 
Ophthalmic pharmaceutical products are typically pack 
aged in multidose form. Preservatives are thus included to 
prevent microbial contamination during use. Suitable preser 
vatives include: polyquaternium-l, benZalkonium chloride, 
thimerosal, chlorobutanol, methyl paraben, propyl paraben, 
phenylethyl alcohol, edetate disodium, sorbic acid, or other 
agents knoWn to those skilled in the art. The use of 
polyquatemium-l as the antimicrobial preservative is pre 
ferred. Typically such preservatives are employed at a level of 
from 0.001% to 1.0% by Weight. 
The solubility of the components of the present composi 
tions may be enhanced by a surfactant or other appropriate 
co-solvent in the composition. Such co-solvents include 
polysorbate 20, 60, and 80, polyoxyethylene/polyoxypropy 
lene surfactants (e.g., Pluronic F-68, F-84 and P-103), cyclo 
dextrin, or other agents knoWn to those skilled in the art. 
Typically such co-solvents are employed at a level of from 
0.01% to 2% by Weight. 
The use of viscosity enhancing agents to provide the topi 
cal compositions of the invention With viscosities greater than 
the viscosity of simple aqueous solutions may be desirable to 
increase ocular absorption of the active compounds by the 
target tissues or increase the retention time in the eye. Such 
viscosity building agents include, for example, polyvinyl 
alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxy 
propyl methylcellulose, hydroxyethyl cellulose, carboxym 
ethyl cellulose, hydroxy propyl cellulose or other agents 
knoW to those skilled in the art. Such agents are typically 
employed at a level of from 0.01% to 2% by Weight. 
The C3a, C3aR, C5a and/or C5aR inactivating agent-con 
taining compositions of the invention can be formulated as 
neutral or salt forms. Pharmaceutically acceptable salts 
include those formed With anions such as those derived from 
hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., 
and those formed With cations such as those derived from 
sodium, potassium, ammonium, calcium, ferric hydroxides, 
isopropylamine, triethylamine, 2-ethylamino ethanol, histi 
dine, procaine, etc. 
The amount of the active agents of the compositions of the 
invention Which Will be effective in the treatment, inhibition 
and/or prevention of neovasculariZation of the eye can be 
determined by standard clinical techniques. In addition, in 
vitro assays may optionally be employed to help identify 
optimal dosage ranges. The precise dose to be employed in 
the formulation Will also depend on the route of administra 
tion, and the seriousness of the neovascular disease or disor 
der, and should be decided according to the judgment of the 
practitioner and each patient’ s circumstances. Effective doses 
may be extrapolated from dose-response curves derived from 
in vitro or animal model test systems. 
Methods of the Invention 
In another aspect of this invention there is provided meth 
ods of treating AMD. In one embodiment there are methods 
for treating and/or preventing CNV comprising administer 
ing to the eye of a subject a therapeutically effective amount 
of the compositions described herein. Preferably, administra 
tion of such one or more antagonist or antibody to C3a, C3aR, 
C5a or C5aR reduces VEGF expression. In another embodi 
ment there is a method of using the compositions described 
herein to 
The compositions may be administered together With other 
biologically active agents. Administration of the composi 
tions of the invention may be systemic or local. Local admin 
istration to the affected eye(s) may be achieved by, for 
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example, and not by Way of limitation, local infusion during 
surgery, transscleral delivery, intravitreous injection, intrac 
ameral injection, subretinal injection, topical application, 
e.g., in conjunction With a Wound dressing after surgery or via 
drops or application of a gel or other topical solution, by 
injection, or by means of an implant, said implant being of a 
porous, non-porous, or gelatinous material, including mem 
branes, such as sialastic membranes, or ?bers. Preferably, 
When administering a protein, including an antibody or func 
tional fragment thereof, of the invention, care must be taken to 
use materials to Which the protein does not absorb. 
In a preferred embodiment, the composition is adminis 
tered by topical application to the eye. The ophthalmic com 
positions are typically administered to the affected eye by 
applying one to four drops of a sterile solution or suspension, 
or a comparable amount of an ointment, gel or other solid or 
semisolid composition, to the surface of the affected eye one 
to four times per day. HoWever, the compositions may also be 
formulated as irrigating solutions that are applied to the 
affected eye during surgical procedures. 
Topical compositions Will typically have a pH in the range 
of 4.5 to 8.0. The ophthalmic compositions must also be 
formulated to have osmotic values that are compatible With 
the aqueous humor of the eye and ophthalmic tissues. Such 
osmotic values Will generally be in the range of from about 
200 to about 400 milliosmoles per kilogram of Water 
(“mOsm/kg”), but Will preferably be about 300 mOsm/kg. 
In another preferred embodiment, the composition is for 
mulated in accordance With routine procedures as a pharma 
ceutical composition adapted for injection intravenously, 
introperitoneally, or intravitreously. In a preferred embodi 
ment, the composition is administered by intravenous injec 
tion. A high dose intravenous immunoglobulin (IVIG), as 
Well as F(ab)2-IVIG and even irrelevant human monoclonal 
antibodies all can bind C3a and C5a and interfere With their 
function. Basta M. et al. F(ab)'2-mediated neutralization of 
C3a and C5a anaphylatoxins: a novel effector function of 
immunoglobulins. Nature Medicine 2003; 91431-8. In 
another preferred embodiment the composition is adapted for 
intravitreous injection to the eye. Typically, compositions for 
injection are solutions in sterile isotonic aqueous buffer. 
Where necessary, the composition may also include a solu 
biliZing agent and a local anesthetic such as lignocaine to ease 
pain at the site of the injection. Generally, the ingredients are 
supplied either separately or mixed together in unit dosage 
form, for example, as a dry lyophiliZed poWder or Water free 
concentrate in a hermetically sealed container such as an 
ampoule or sachette indicating the quantity of active agent. 
Where the composition is to be administered by infusion, it 
can be dispensed With an infusion bottle containing sterile 
pharmaceutical grade Water or saline. Where the composition 
is administered by injection, an ampoule of sterile Water for 
injection or saline can be provided so that the ingredients may 
be mixed prior to administration. 
A controlled release system may also be used to effect local 
administration. In one embodiment, a pump may be used (see 
Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 
(1987); BuchWald et al., Surgery 88:507 (1980); Saudek et 
al., N. Engl. J. Med. 321:574 (1989)). In another embodi 
ment, polymeric materials can be used (see Medical Appli 
cations of Controlled Release, Langer and Wise (eds.), CRC 
Pres., Boca Raton, Fla. (1974); Controlled Drug Bioavailabil 
ity, Drug Product Design and Performance, Smolen and Ball 
(eds.), Wiley, NeW York (1984); Ranger and Peppas, 1., Mac 
romol. Sci. Rev. Macromol. Chem. 23:61 (1983); see also 
Levy et al., Science 228:190 (1985); During et al., Ann. 
Neurol. 25:351 (1989); HoWard et al., J. Neurosurg. 71:105 
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(1989)). In yet another embodiment, a controlled release sys 
tem can be placed in proximity of the eye. 
Various other delivery systems are known and can be used 
to administer a composition of the invention, e.g., encapsu 
lation in vesicles, liposomes, microparticles, microcapsules, 
recombinant cells capable of expressing the compound, 
receptor-mediated endocytosis (See, e. g., Wu and Wu, J. Biol. 
Chem. 262:4429-4432 (1987)), construction of a nucleic acid 
as part of a retroviral or other vector, etc. In one embodiment, 
the composition of the invention can be delivered in a vesicle, 
in particular a liposome (See Langer, Science 249: 1 527-1 533 
(1990); Treat et al., in Liposomes in the Therapy of Infectious 
Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, 
NeW York, pp. 353-365 (1989); Lopez-Berestein, ibid., pp. 
317-327; see generally ibid.). 
Diagnostics of the Invention 
The present invention further provides in vitro and in vivo 
diagnostic methods, assays and kits. Such methods are appli 
cable for use in generating diagnostic, prognostic or imaging 
information for any neovascular disease, as exempli?ed by 
age-related macular degeneration. 
In one embodiments, the present invention concerns 
immunodetection methods for binding, purifying, removing, 
quantifying or otherWise generally detecting C3a, C3aR, C5a 
and/or C5aR and for diagnosing neovascular disease, like 
AMD, of the eye. The antibodies to C3a, C3aR, C5a and 
C5aR of the present invention may be employed to detect 
C3a, C3aR, C5a and/ or C5aR, respectively, in vivo (see 
beloW), in isolated issue samples, biopsies or sWabs and/or in 
homogenized tissue samples. Such immunodetection meth 
ods have evident diagnostic utility, but also have applications 
to non-clinical samples, such as in the titering of antigen 
samples, and the like. 
The steps of various useful immunodetection methods 
have been described in the scienti?c literature, such as, e.g., 
Nakamura et al. (1987). In general, the immunobinding meth 
ods include obtaining a sample suspected of containing C3a 
and/or C5a and contacting the sample With C3a and/or C5a 
antibodies under conditions effective to alloW the formation 
of immunocomplexes. In such methods, the antibody may be 
linked to a solid support, such as in the form of a column 
matrix, and the sample suspected of containing C3a and/or 
C5a Will be applied to the immobilized antibody. 
More preferably, the immunobinding methods include 
methods for detecting or quantifying the amount of C3a, 
C3aR, C5a and/ or C5aR in a sample, Which methods require 
the detection or quanti?cation of any immune complexes 
formed during the binding process. Here, one Would obtain a 
sample suspected of containing C3a, C3aR, C5a and/or C5aR 
and contact the sample With an antibody in accordance here 
With and then detect or quantify the amount of immune com 
plexes formed under the speci?c conditions. 
The biological sample analyzed may be any sample that is 
suspected of containing C3a, C3aR, C5a and/or C5aR, gen 
erally from an animal or patient suspected of having an 
neovascular disease. The samples may be a ?uid, tissue sec 
tion or specimen, a biopsy, a sWab or smear test sample, a 
homogenized tissue extract or separated or puri?ed forms of 
such. A sample can be a liquid such as ?uids of the eye such 
as tears, urine, saliva, cerebrospinal ?uid, blood, serum or the 
like; a solid or semi-solid such as vitreous humor, tissues, 
feces, or the like; or, alternatively, a solid tissue such as those 
commonly used in histological diagnosis. Preferably, the 
sample is a sample from plasma, serum, or the vitreous 
humor, subretinal space, anterior changer, tear ?lm of the eye. 
Introducing the chosen biological sample to the antibody 
under conditions effective and for a period of time su?icient 
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to alloW the formation of immune complexes (primary 
immune complexes) is generally a matter of simply adding an 
antibody composition to the sample and incubating the mix 
ture for a period of time lone enough for the antibodies to 
form immune complexes With, i.e., to bind to, any C3a, C3aR, 
C5a and/or C5aR present. After this time, the sample-anti 
body composition, such as a tissue section, ELISA plate, dot 
blot or Western blot, Will generally be Washed to remove any 
non-speci?cally bound antibody species, alloWing only those 
antibodies speci?cally bound Within the primary immune 
complexes to be detected. 
Immunoassays of the present invention Which utilize the 
monoclonal antibodies are competitive and non-competitive 
immunoassays in either a direct or indirect format, forWard, 
reverse, or simultaneous modes, including, the radioimmu 
noassay (RIA) and the sandWich (immunometric) assay and 
immunohistochemical assays on physiological samples. 
Those of skill in the art Will knoW, or can readily discern, other 
immunoassay formats Without undue experimentation. 
The detection of immunocomplex formation is also Well 
knoWn in the art and may be achieved through the application 
of numerous approaches. These methods are generally based 
upon the detection of a label or marker, such as any radioac 
tive, ?uorescent, biological or enzymatic tags or labels knoWn 
in the art. Exemplary US. patents concerning the use of such 
labels include US. Pat. Nos. 3,817,837; 3,850,752; 3,939, 
350; 3,996,345; 4,277,437; 4,275,149 and 4,366,241. Theuse 
of enzymes that generate a colored product upon contact With 
a chromogenic substrate are generally preferred. Secondary 
binding ligand, such as a second antibody or a biotin/avidin or 
biotin/streptavidin ligand binding arrangement, may also be 
used, as is knoWn in the art. 
The anti-C3a, anti-C3aR, anti-C5a, and/ or anti-C5aR anti 
bodies employed in the detection may themselves be opera 
tively attached to a detectable label, Wherein one Would then 
simply detect this label, thereby alloWing the amount of the 
primary immune complexes in the composition to be deter 
mined. 
In one embodiment the primary immune complexes are 
detected by means of a second binding ligand that has binding 
a?inity for the antibodies of the invention. In such cases, the 
second binding ligand may be operatively attached to a 
detectable label. The second binding ligand is itself often an 
antibody, and may thus be termed a “secondary” antibody. 
The primary immune complexes are contacted With the 
labeled, secondary binding ligand, or antibody, under condi 
tions effective and for a period of time su?icient to alloW the 
formation of secondary immune complexes. The secondary 
immune complexes are then generally Washed to remove any 
non-speci?cally bound labeled secondary antibodies or 
ligands, and the remaining label in the secondary immune 
complexes is then detected. 
Further methods include the detection of primary immune 
complexes by a tWo step approach. A second binding ligand, 
such as an antibody, that has binding a?inity for the ?rst 
antibody is used to form secondary immune complexes, as 
described above. After Washing, the secondary immune com 
plexes are contacted With a third binding ligand or antibody 
that has binding af?nity for the second antibody, again under 
conditions effective and for a period of time su?icient to alloW 
the formation of immune complexes (tertiary immune com 
plexes). The third ligand or antibody is operatively attached to 
a detectable label, alloWing detection of the tertiary immune 
complexes thus formed. This system may provide for signal 
ampli?cation if desired. 
In the clinical diagnosis or monitoring of patients With an 
neovascular disease, the detection of C3a, C3aR, C5a, and/or 
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C5aR, or an increase in the levels of C3a, C3aR, C5a and/or 
C5aR, in comparison to the levels in a corresponding biologi 
cal sample from a normal subject is indicative of a patient 
With an neovascular disease. 
HoWever, as is knoWn to those of skill in the art, such a 
clinical diagnosis Would not likely be made on the basis of 
this method in isolation. Those of skill in the art are very 
familiar With differentiating betWeen signi?cant expression 
of a biomarker, Which represents a positive identi?cation, and 
loW level or background expression of a biomarker. Indeed, 
background expression levels are often used to form a “cut 
off” above Which increased staining Will be scored as signi? 
cant or positive. 
The in vivo diagnostic or imaging methods generally com 
prise administering or introducing to a patient a diagnosti 
cally effective amount of a C3a, C3aR, C5a and/or C5aR 
antibody that is operatively attached to a marker or label that 
is detectable by non-invasive methods. The antibody-marker 
conjugate is alloWed su?icient time to localiZe and bind to 
C3a, C3aR, C5a and/or C5aR Within the eye. The patient is 
then exposed to a detection device to identify the detectable 
marker, thus forming an image of the location of C3a, C3aR, 
C5a and/ or C5aR in the eye of a patient. The presence of C3a, 
C3aR, C5a, C5aR or a combination thereof is detected by 
determining Whether an antibody-marker binds to a compo 
nent of the eye. Detection of or an increased level in C3a, 
C3aR, C5a, C5aR or a combination thereof in comparison to 
a normal individual Without neovascular disease is indicative 
of a predisposition for and/or on set of neovascular disease. In 
a preferred embodiment of the invention there is provided an 
in vivo assay for detecting the presence of C3a, C3aR, C5a, or 
C5aR as a predisposition for or early detection of AMD. 
These aspects of the invention are also preferred for use in eye 
imaging methods and combined angiogenic diagnostic and 
treatment methods. 
The anit-C3a, anti-C3aR, anti-C5a, and/ or anti-C5aR anti 
bodies or binding compounds or ligands for the in vivo detec 
tion of C3a, C3aR, C5a and/or C5aR, respectively, are given 
in a dose Which is diagnostically effective. The concentration 
of detectably labeled antibody or compound Which is admin 
istered should be suf?cient such that the binding to C3a, 
C3aR, C5a, or C5aR and/or C3a-, C3aR-, C5a- and/or C5aR 
bearing cells, is detectable compared to the background. Fur 
ther, it is desirable that the detectably labeled antibody or 
compound be rapidly cleared from the circulatory system in 
order to give the best target-to-background signal ratio. 
Dosages for in vivo imaging embodiments are generally 
less than for therapy, but are also dependent upon the age, 
gender, Weight and extent of disease of a patient. One time 
doses should be su?icient. The dosage of the compound can 
vary from about 0.01 mg/kg to about 500 mg/kg, preferably 
about 0.1 mg/kg to about 200 mg/kg, most preferably about 
0.1 mg/kg to about 10 mg/kg. Such dosages may vary, for 
example, depending on Whethermultiple injections are given, 
on the tissue being assayed, and other factors knoWn to those 
of skill in the art. 
For in vivo diagnostic imaging, the type of detection instru 
ment available is a major factor in selecting an appropriate 
label or marker, like a radioisotope. The radioisotope chosen 
must have a type of decay Which is detectable for the given 
type of instrument. Still another important factor in selecting 
a radioisotope for in vivo diagnosis is that the half-life of the 
radioisotope be long enough such that it is still detectable at 
the time of maximum uptake by the target, but short enough 
such that deleterious radiation With respect to the host is 
acceptable. Ideally, a radioisotope used for in vivo imaging 
Will lack a particle emission but produce a large number of 
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photons in the 140-250 keV range, Which may be readily 
detected by conventional gamma cameras. 
In antibody conjugates for in vivo diagnostic protocols 
markers or labels are required that can be detected using 
non-invasive methods. Many appropriate detectable markers 
or labels are knoWn in the art, as are methods for their attach 
ment to antibodies and binding ligands (see, e.g., U.S. Pat. 
Nos. 5,021,236 and 4,472,509). Examples of such labels 
include those that are, absorbant-based, chemiluminescent, 
?uorescent, nuclear magnetic spin-resonance, paramagnetic, 
radioactive, x-ray detectable, or a combination of the forego 
ing. Certain attachment methods involve the use of a metal 
chelate complex employing, for example, an organic chelat 
ing agent such a DTPA attached to the antibody (U .8. Pat. No. 
4,472,509). Monoclonal antibodies may also be reacted With 
an enZyme in the presence of a coupling agent such as glut 
araldehyde or periodate. Conjugates With ?uorescein markers 
are prepared in the presence of these coupling agents or by 
reaction With an isothiocyanate. 
An example of detectable labels are the paramagnetic ions. 
In this case, suitable ions include chromium (III), manganese 
(II), iron (III), iron (II), cobalt (II), nickel (II), copper (II), 
neodymium (III), samarium (III), ytterbium (III), gadolinium 
(III), vanadium (II), terbium (III), dysprosium (III), holmium 
(III) and erbium (III), With gadolinium being particularly 
preferred. 
Ions useful in other contexts, such as X-ray imaging, 
include but are not limited to lanthanum (III), gold (III), lead 
(II), and especially bismuth (III). Fluorescent labels include 
rhodamine, ?uorescein and renographin. Rhodamine and 
?uorescein are often operatively attached via an isothiocyan 
ate intermediate. 
In the case of radioactive isotopes for diagnostic applica 
tions, suitable examples include l4carbon, 51chromium, 
36chlorine, 57cobalt, 58cobalt, copper67, 152Eu, gallium67, 
gallium68, 3hydrogen, iodine123, iodinel25, iodinel3l, 
indiuml 13, indiuml 1 3 , 5 9iron, mercuryl97, mercury2O3, 
32pho sphorus, rheniuml 86, rheniuml 88, rubidium97, 
rubidiuml O3 , 75 selenium, 3 5 sulphur, technetium99’" and 
yttriumgo. 125 I is often being preferred for use in certain 
embodiments, and technicium99’" and indiunl l l are also often 
preferred due to their loW energy and suitability for long range 
detection. 
In the case of nuclear magnetic spin-resonance isotope, 
suitable examples include cobalt (II), copper (II), chromium 
(III), dysprosium (III), erbium (III), gadolinium (III), hol 
mium (III), iron (II), iron (III), manganese (II), neodymium 
(III), nickel (II), samarium (III), terbium (III), vanadium (II) 
or ytterbium (III); or rhodamine or ?uorescein. 
Radioactively labeled C3a and/ or C5a antibodies for use in 
the present invention may be produced according to Well 
knoWn methods in the art. For instance, intermediary func 
tional groups that are often used to bind radioisotopic metallic 
ions to antibodies are diethylenetriaminepentaacetic acid 
(DTPA) and ethylene diaminetetracetic acid (EDTA). 
Monoclonal antibodies can also be iodinated by contact 
With sodium or potassium iodide and a chemical oxidiZing 
agent such as sodium hypochlorite, or an enZymatic oxidiZing 
agent, such as lactoperoxidase. Antibodies according to the 
invention may be labeled With technetium-99em by ligand 
exchange process, for example, by reducing pertechnate With 
stannous solution, chelating the reduced technetium onto a 
Sephadex column and applying the antibody to this column; 
or by direct labeling techniques, e.g., by incubating pertech 
nate, a reducing agent such as SNCl2, a buffer solution such as 
sodium-potassium phthalate solution, and the antibody. 
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Any of the foregoing type of detectably labeled anti-C3a, 
anti-C3aR, anti-C5a and/or anti-C5aR antibodies may be 
used in the imaging or combined imaging and diagnostic 
aspects of the present invention. They are equally suitable for 
use in in vitro diagnostics. 
In still another aspect, the present invention provides diag 
nostic kits, including both immunodetection and imaging 
kits, for use With the immunodetection and imaging methods 
described above. Accordingly, the anti-C3a, anti-C3aR, anti 
C5a and/or anti-C5aR antibodies are provided in the kit, 
generally comprised Within a suitable container. 
For immunodetection, the antibodies may be bound to a 
solid support, such as a Well of a microtitre plate, although 
antibody solutions or poWders for reconstitution are pre 
ferred. The immunodetection kits preferably comprise at least 
a ?rst immunodetection reagent. The immunodetection 
reagents of the kit may take any one of a variety of forms, 
including those detectable labels that are operatively attached 
to the given antibody. Detectable labels that are associated 
With or attached to a secondary binding ligand are also con 
templated. Exemplary secondary ligands are those secondary 
antibodies that have binding a?inity for the ?rst antibody. 
Further suitable immunodetection reagents for use in the 
present kits include the tWo-component reagent that com 
prises a secondary antibody that has binding a?inity for the 
?rst antibody, along With a third antibody that has binding 
a?inity for the second antibody, the third antibody being 
operatively attached to a detectable label. As noted above, a 
number of exemplary labels are knoWn in the art and all such 
labels may be employed in connection With the present inven 
tion. These kits may contain antibody-label conjugates either 
in fully conjugated form, in the form of intermediates, or as 
separate moieties to be conjugated by the user of the kit. 
The imaging kits Will preferably comprise an antibody to 
C3a, C3aR, C5a and/ or C5aR that is already attached to an in 
vivo detectable label. HoWever, the label and attachment 
means could be separately supplied. 
Either kit may further comprise control agents, such as 
suitably aliquoted compositions of C3a, C3aR, C5a and/or 
C5aR, Whether labeled or unlabeled, as may be used to pre 
pare a standard curve for a detection assay. The components 
of the kits may be packaged either in aqueous media or in 
lyophiliZed form. 
The container means of the kits Will generally include at 
least one vial, test tube, ?ask, bottle, syringe or other con 
tainer means, into Which the antibody or antigen may be 
placed, and preferably, suitably aliquoted. Where a second or 
third binding ligand or additional component is provided, the 
kit Will also generally contain a second, third or other addi 
tional container into Which this ligand or component may be 
placed. The kits may also include other diagnostic reagents 
for use in the diagnosis of any one or more neovascular 
diseases. 
The kits of the present invention Will also typically include 
a means for containing the antibody, and any other reagent 
containers in close con?nement for commercial sale. Such 
containers may include injection or bloW-molded plastic con 
tainers into Which the desired vials are retained. 
In another aspect of the invention there is provided a cell 
monitoring method utiliZing the antibodies and compounds/ 
ligands in vitro and in vivo to monitor the course of therapy 
for neovascular disease, like AMD. Thus, for example, by 
measuring the increase or decrease in the biological mol 
ecules associated With such a diseases or changes in the 
concentration of C3a, C3aR, C5a and/or C5aR, or C3a-, 
C3aR-, C5a- and/or C5a-bearing cells present in the eye or in 
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various eye ?uids, it Would be possible to determine Whether 
a particular therapeutic regimen aimed at ameliorating the 
AMD is effective. 
EXAMPLES 
The folloWing examples are presented for the illustrative 
purposes and it is to be understood that the present invention 
is not limited to those precise embodiments. It should be 
appreciated by those of skill in the art that the techniques 
disclosed in the examples Which folloW represent techniques 
to function Well in the practice of the invention, and thus can 
be considered to constitute preferred modes for its practice. 
HoWever, those of skill in the art should, in light of the present 
disclosure, appreciate that many changes can be made in the 
speci?c embodiments Which are disclosed and still obtain a 
like or similar result Without departing from the spirit and 
scope of the invention. 
Example 1 
Animals 
Male C3aR_/_ and C5aR_/_ mice, backcrossed 6 times to 
C57BL/6J, generated as described previously (Hopken, U. E., 
et al. (1996) Nature 383, 86-9; and Humbles, A. A., et al., 
(2000) Nature 406, 998-1001), andWild-type C57BL/6J mice 
(Jackson Labs) betWeen 6 and 8 Weeks of age Were used to 
minimiZe variability. For all procedures, anesthesia Was 
achieved by intramuscular injection of 50 mg/kg ketamine 
hydrochloride (Ft. Dodge Animal Health) and 10 mg/kg xyla 
Zine (Phoenix Scienti?c), and pupils Were dilated With topical 
1% tropicamide (Alcon). 
Example 2 
CNV 
Laser photocoagulation (532 nm, 200 mW, 100 ms, 75 um) 
(OcuLight GL, Iridex) Was performed (volume studies: 
3/eye; protein analyses/?ow cytometry: 12/ eye) on both eyes 
of each animal to induce CNV as previously described in 
Sakurai, E., Taguchi, H., Anand, A., Ambati, B. K., Gragou 
das, E. S., Miller, J. W., Adamis, A. P. & Ambati, J. (2003) 
Invest Ophthalmol l/zs Sci 44, 2743-9; and Sakurai, E.,Anand, 
A., Ambati, B. K., van Rooijen, N. &Ambati, J. (2003) Invest 
Ophthalmol Vis Sci 44, 3578-85. CNV volumes Were mea 
sured by scanning laser confocal microscope (TCS SP, Leica) 
as previously reported (Id.) With 0.5% FITC-Grz?bnia sim 
plicifolia Isolectin B4 (Vector Laboratories) or 0.5% FITC 
rat antibody against mouse CD3 1 (BD Phar'mingen).Volumes 
obtained by lectin and CD31 staining Were highly correlated 
(r2:0.95). 
Example 3 
Complement Inhibition 
The C3a receptor antagonist (C3aRA) N2-[(2,2-diphe 
nylethoxy)acetyl]-arginine (Ames, R. S., Lee, D., Foley, J. J ., 
JureWicZ, A. J ., Tometta, M. A., Bautsch, W., Settmacher, B., 
Klos, A., Erhard, K. E, Cousins, R. D., SulpiZio, A. C., 
Hieble, J. P., McCaffer‘ty, G., Ward, K. W., Adams, J. L., 
Bondinell, W. E., Underwood, D. C., Osborn, R. R., Badger, 
A. M. & Sarau, H. M. (2001).]Immun0l 166, 6341-6348) and 
C5a receptor antagonist (C5aRA) AcF[OPdChaWR] (Finch, 
A. M., Wong,A. K., PacZkoWski, N. J., Wadi, S. K., Craik, D. 
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J., Fairlie, D. P. & Taylor, S. M. (1999) JMed Chem 42, 
1965-74), Were synthesized as previously described (Reca, 
R., Mastellos, D., Majka, M., Marquez, L., Ratajczak, J., 
Franchini, S., Glodek, A., Honczarenko, M., Spruce, L. A., 
JanoWska-Wieczorek, A., Lambris, J. D. & Ratajczak, M. Z. 
(2003) Blood 101, 3784-93; Mastellos, D., Papadimitriou, J. 
C., Franchini, S., Tsonis, P. A. & Lambris, J. D. (2001) J 
Immunol 166, 2479-86). A nonsense peptide (IAVVQD 
WGHHRAT), synthesized as described previously (Sahu, A., 
Soulika, A. M., Morikis, D., Spruce, L., Moore, W. T. & 
Lambris, J. D. (2000) Jlmmunol 165, 2491-9), Was used as 
control. Rat IgG2a antibody against mouse C3a (clone 3/11; 
Hycult Biotechnology), Which inhibits C3a activity (unpub 
lished data, J.D.L.), and rabbit polyclonal IgG antibody 
against a synthetic peptide constructed from the carboxyl 
terminal region of rat C5a (Huber-Lang, M. S., Sarma, J. V., 
McGuire, S. R., Lu, K. T., Guo, R. E, Padgaonkar, V. A., 
Younkin, E. M., Laudes, I. J ., Riedemann, N. C.,Younger, J. 
G. & Ward, P. A. (2001) FASEB J 15, 568-70), Which also 
inhibits mouse C5a (unpublished data, J .V.S.), and Were used 
to block C3a and C5a. Rabbit IgG and rat IgG2a (Jackson 
Immunoresearch) Were used as controls. These reagents Were 
injected into the vitreous humor of Wild-type mice using a 
33-gauge Hamilton syringe either immediately after or three 
days after laser injury. 
Example 4 
Immunohistochemistry 
Frozen sections ?xed in Histochoice MB (Amresco) and 
blocked With 5% donkey serum (Jackson lmmunoresearch) 
Were stained With chicken antibodies against mouse C3 
(1:750) or C5 (1 :5,000; both gifts ofS. R. Barnum, University 
of Alabama, Birmingham). Bound antibody Was detected 
With Cy3-donkey secondary (1:750; Jackson Immunore 
search). Rabbit antibody against mouse RPE65 (1 :1,000; gift 
of M. Redmond, National Eye Institute, Bethesda) in con 
junction With Alexa 488-donkey secondary (1 :200; Molecu 
lar Probes) Was used to localize RPE cells. Cell nuclei Were 
stained With 4',6'-diamino-phenylindole (DAPI; Molecular 
Probes). 
Example 5 
Cell Culture 
Human RPE cells (gift of David R. Hinton, University of 
Southern California) Were cultured in Dulbecco’s modi?ed 
essential medium (Invitrogen) containing 10% fetal bovine 
serum, penicillin G (100 U/ml), streptomycin sulfate (0.1 
mg/ml) (all from Sigma-Aldrich) at 370 C. under 10% CO2 
and 90% room air. Cells Were used for experiments upon 
attaining 80% or 100% con?uence. 
Example 6 
VEGF ELISA 
The RPE/ choroid complex Was dissected from the mouse 
eye and sonicated in lysis buffer (20 mM imidazole HCl, 10 
mM KCl, 1 mM MgCl2, 10 mM EGTA, 1% Triton X-100, 10 
mM NaF, 1 mM Na molybdate, 1 mM EDTA With protease 
inhibitor (Sigma-Aldrich)) on ice for 45 sec. VEGF protein 
levels (pg/ml) in the RPE cell culture supernatant or the 
RPE/choroid lysate Were determined by ELISA (R&D Sys 
tems) and normalized to total protein (pg/ml) (Bio-Rad). 
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Example 7 
Western Blotting 
Equal amounts of total protein from RPE/choroid Were 
resolved in SDS 4-20% polyacrylamide gradient gel and 
transferred to nitrocellulose membranes for Western blotting 
With chicken antibodies to mouse C3 or mouse C5 (1: 100; gift 
of S. R. Barnum, University of Alabama, Birmingham). 
Equal loading Was assessed by blotting With rabbit antibody 
to human GAPDH (1 :2,000; Abcam). 
Example 8 
FloW Cytometry 
Single cell suspensions isolated from mouse RPE/choroids 
via collagenase D treatment (20 U/mL; Roche Diagnostics) 
Were incubated in Fc block (0.5 mg/mL; BD Pharmingen) for 
15 min on ice, stained With Cy5 -rat antibody to mouse F4/ 80 
(1 :30; Serotec), FITC-hamster antibody to mouse CD1 1c 
(1:100; Serotec), or PE-rat antibody to mouse Gr-1 (1:200; 
eBioscience), and subjected to FACS analysis (FACScalibur, 
BD Biosciences). Macrophages and neutrophils Were de?ned 
as F4/80+CD1 1c- and Gr-1+F4/80-cells, respectively. 
Example 9 
StatisticsiVolume of CNV 
Because the probability of each laser lesion developing 
CNV is in?uenced by the group to Which it belongs, the 
mouse, the eye, and the laser spot, the mean lesion volumes 
Were compared using a linear mixed model With a split plot 
repeated measures design, as previously described. Id. The 
Whole plot factor Was the genetic group to Which the animal 
belonged While the split plot factor Was the eye. Statistical 
signi?cance Was determined at the 0.05 level. Post hoc com 
parison of means Was constructed With a Bonferroni adjust 
ment for multiple comparisons. 
Example 10 
Protein Levels and FloW Cytometry 
VEGF protein data are represented as the meanis .e.m. of at 
least 3 independent experiments and compared using a tWo 
tailed Student’s t-test. The null hypothesis Was rejected at 
P<0.05. 
Example 11 
Diagnostic Assay 
Anti-C3a, anti-C3aR, anti-C5a and/or anti C5aR antibod 
ies are labeled With ?uorescein, indocyanine green, or conju 
gates thereof. The labeled antiC3a and C5a antibodies or Fab 
fragments thereof are injected into the vitreous humor of the 
eye or intravenously and detected by ?uorescent imaging 
using appropriate excitation and emission ?lters through a 
dilated pupil. 
What is claimed is: 
1. A pharmaceutical composition for treating and/or pre 
venting choroidal neovascularization (CNV) comprising, a 
therapeutically effective amount of an antibody that binds 
selectively to the receptor of C3a (C3aR), and prevents cho 
roidal neovascularization and an ophthalmically acceptable 
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pharmaceutical carrier, wherein the antibody comprises a 4. The composition of claim 3 Wherein the radioisotope is 
pharmaceutical agent operatively attached thereto. 21 lAstatine or 131Iodine. 
2. The composition according to claim 1 Wherein the phar- 5. The composition of claim 1 Wherein said composition is 
maceutical agent is an anti-in?ammatory agent. formulated for intravitreous injection. 
3. The composition of claim 1 Wherein the pharmaceutical 5 
agent is a radioisotope. * * * * * 
